Table 1.

Main differences between 2006 revised Sapporo and 2023 ACR/EULAR classification criteria for antiphospholipid syndrome.

	2006 Revised Sapporo	2023 ACR/EULAR
Classification	At least 1 clinical criterion AND 1 laboratory criterion	3 points from clinical domains AND at least 3 points from laboratory domains
Clinical criteria		Entry criteria and scoring: count the highest weighted criterion towards the total score
	2 clinical criteria 1. Vascular thrombosis: One or more clinical episodes of arterial, venous, or small vessel thrombosis, in any tissue or organ 2. Pregnancy morbidity	6 clinical domains 1. Macrovascular-Venous Thromboembolism 2. Macrovascular-Arterial Thrombosis 3. Microvascular 4. Obstetric 5. Cardiac Valve 6. Hematology
Considered as non-criteria-manifestations:
- Heart valve disease	Yes	No
- Livedo racemosa	Yes	No
- Thrombocytopenia	Yes	No
- Nephropathy,	Yes	No
- Neurological manifestations	Yes	Yes
- Pulmonary/Adrenal hemorrhage	Yes	No
Laboratory criteria
Persistent positivity (at 12 weeks)	Yes	Yes
Timeline of aPL positivity and clinical criteria	Less than 5 years of clinical criteria	Within 3 years of clinical criterion
Thresholds of aCL and/or aβ2GPI	aCL: >40 GPL or MPL, or >the 99th percentile aβ2GPI: >the 99th percentile	aCL or aβ2GPI: Moderate 40–79 units High >80 units
Antibodies for laboratory criteria:
- Positive LA	Yes	Yes
- IgG aCL or aβ2GPI	Yes	Yes
- IgM aCL and/or aβ2GPI	Yes	Yes. If isolated: are not sufficient (weight only 1 point)

aCL: anticardiolipin antibody, aβ2GPI: anti-β2 glycoprotein I antibody, LA: lupus anticoagulant.